ClinicalTrials.gg
RecruitingNCT06908928Updated Oct 28, 2026

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

A Phase 1 interventional study of bulumtatug fuvedotin and bulumtatug fuvedotin in Triple Negative Breast Cancer, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 28, 2026Study contact changedSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 163 open to participants now, 264 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.

Planned enrollment
301st of 605
52 · median 52
Started
2025
with 46 others
Phase 1
246 of 645
52 open now
Primary completion
2027-05
later than 123 of 263 live
Registered
579th of 645
by date

Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 301st largest by planned enrollment of the 605 interventional ones that give a count, is one of 47 that started in 2025, is one of 246 in phase 1, reaches primary completion later than 123 of the 263 other live ones, and was the 579th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

163 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Triple Negative Breast Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.

03

Conditions studied

  • Triple Negative Breast Cancer

Keywords

  • 9MW2821
  • bulumtatug fuvedotin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has by v1.1
  • Recurrent or triple-negative breast cancer patients as per current ASCO/CAP guidelines
  • Patient has received prior treatment with a taxane and an antibody-drug conjugate with a topoisomerase inhibitor payload.
  • Patient has received no more than 3 prior lines of cytotoxic therapy in the locally advanced or metastatic setting.
  • Provision of or fresh tumor biopsy.
  • Capable of giving
  • Male or female subjects aged ≥ 18 years.
  • Subjects must be willing to receive blood transfusions if medically indicated.
  • 0-1
  • Adequate hematologic and organ function
  • of at least 3 months as assessed by the investigator
  • Compliance with requirement

Exclusion criteria

Exclusion Criteria:

  • Have received any prior treatment with enfortumab vedotin, tisotumab vedotin or other MMAE based or nectin-4 targeted antibody-drug conjugates.
  • Unstable requiring treatment in the last 28 days.
  • Acute infection requiring IV treatment in the last 14 days.
  • Grade ≥2 peripheral neuropathy.
  • Pregnant or breastfeeding women.
  • Life-threatening illness or uncontrolled medical conditions that could compromise the subject's safety or put the study outcomes at risk
  • Any systemic anticancer therapy in the last 28 days prior to first administration of study drug.
  • Active , or infection unless well controlled with anti-viral therapy.
  • Active or chronic corneal disorder, keratitis, corneal ulcerations or Sjogren's syndrome.
  • Have any ongoing acute inflammatory skin disease or chronic skin disease not well controlled.
  • Have been diagnosed with another primary except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non- prostate cancer; or subjects with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.
  • Have significant, uncontrolled or active cardiovascular disease
  • Have active or a history of pneumonitis or interstitial lung disease that requires treatment. Patients with radiation pneumonitis that does not require treatment is allowed.
  • Have uncontrolled diabetes.
  • Have received any strong inhibitors within 14 days prior to the first dose of study drug.
  • Subjects known to be hypersensitive to bulumtatug fuvedotin or to any components of the formulation.
  • History of drug abuse including narcotic and psychiatric drugs within 12 months prior to screening.
  • Have received a within 30 days of planned start of study therapy.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Dose level 1 of BFv

    Drug: bulumtatug fuvedotin

  • Experimental
    Dose level 2 of BFv

    Drug: bulumtatug fuvedotin

Interventions

  • given via intravenous infusion on day 1 and day 8 of every 21-day cycle at dose level 1

  • given via intravenous infusion on day 1 and day 8 of every 21-day cycle at dose level 2

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Objective Response Rate according to RECIST v1.1 by investigator assessment

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Disease control rate

    The percentage of patients who achieve complete response (CR), partial response (PR), or stable disease (SD) as per RECIST v1.1.

    Time frame: Up to approximately 2 years

  2. Clinical benefit rate

    The percentage of patients who achieve CR, PR, or SD for at least 6 months.

    Time frame: Up to approximately 2 years

  3. Duration of response

    The time from first documented response (CR or PR) to disease progression or death, whichever occurs first.

    Time frame: Up to approximately 2 years

  4. Progression-free survival

    The time from treatment initiation to disease progression or death from any cause.

    Time frame: Up to approximately 2 years

  5. Overall survival

    The time from treatment initiation to death from any cause.

    Time frame: Up to approximately 2 years

  6. Time to Maximum Concentration (Tmax)

    Time to reach the maximum observed concentration of bulumtatug fuvedotin, TAb, and MMAE in blood.

    Time frame: Up to approximately 2 years

  7. Maximum Concentration (Cmax)

    Maximum observed blood concentration of bulumtatug fuvedotin, TAb, and MMAE.

    Time frame: Up to approximately 2 years

  8. Half-life (t1/2)

    The time required for the blood concentration of bulumtatug fuvedotin, TAb, and MMAE to decrease by 50%.

    Time frame: Up to approximately 2 years

  9. Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Concentration (AUC0-t)

    The area under the plasma concentration-time curve from time zero to the last measurable concentration for bulumtatug fuvedotin, TAb, and MMAE.

    Time frame: Up to approximately 2 years

  10. Incidence, rate and severity of treatment-emergent adverse events.

    Incidence, rate and severity of AE, SAE, TRAE and AESI. Frequency of clinically significant abnormalities in physical examination, safety laboratory tests, urinalysis, vital signs, and 12-Lead ECG record. Safety will be reported as incidence and rate of treatment-emergent adverse events using NCI CTCAE v5.0 criteria.

    Time frame: Up to approximately 2 years

  11. Immunogenicity

    Incidence and rates of ADA and Nab.

    Time frame: Up to approximately 2 years

  12. Immunogenicity

    Titre of ADA and Nab.

    Time frame: Up to approximately 2 years

Other outcomes

  1. Efficacy parameters and biomarkers including but not limited to nectin-4 expression level.

    The proportion of nectin-4 positive and negative patients. The proportion of nectin-4 positive patients who experienced objective response. The proportion of nectin-4 negative patients who experienced objective response.

    Time frame: Up to approximately 2 years

07

Study locations

6 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for May 2027, 21 months after the start.

Of 136 industry-sponsored phase 1 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 70. This study's planned 21 months is below that.

Counting every sponsor, half of 209 studies reached it within 54 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2025
First posted
Apr 3, 2025
StartActual
Aug 11, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. Massachusetts General Hospital is now Withdrawn
Show site
  • Sarah Cannon Research Institute (SCRI) · Nashville, United States
Oct 23, 2026
Contact
Study contact changed: added e•••@mabwell.com. See the current contact
across 2 updates, Oct 23, 2026 – Oct 28, 2026
Site contacts
Changed at 5 sites. See the sites
Show 5 sites
  • City of Hope · Duarte, United StatesContact person changed (no phone or email listed)
  • UCSD Moores Cancer Center · La Jolla, United StatesContact person changed (no phone or email listed)
  • Anschutz Medical Center · Aurora, United StatesContact added T•••@cuanschutz.eduContact added (no phone or email listed)
  • UChicago Medicine Comprehensive Cancer Center · Chicago, United StatesContact person changed (no phone or email listed)
  • Memorial Sloan Kettering Cancer Center · New York, United StatesContact person changed (no phone or email listed)
Oct 23, 2026
Show all 2 updates
  1. Oct 28, 2026
    Contact Study contact changed: added e•••@mabwell.com. See the current contact
  2. Oct 23, 2026
    1 site added. Massachusetts General Hospital is now Withdrawn
    Show site
    • Sarah Cannon Research Institute (SCRI) · Nashville, United States
    Contact Study contact changed: f•••@mabwell.com · •••6763→m•••@mabwell.com · •••4911; removed w•••@mabwell.com. See the current contact
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • City of Hope · Duarte, United StatesContact person changed (no phone or email listed)
    • UCSD Moores Cancer Center · La Jolla, United StatesContact person changed (no phone or email listed)
    • Anschutz Medical Center · Aurora, United StatesContact added T•••@cuanschutz.eduContact added (no phone or email listed)
    • UChicago Medicine Comprehensive Cancer Center · Chicago, United StatesContact person changed (no phone or email listed)
    • Memorial Sloan Kettering Cancer Center · New York, United StatesContact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06908928
Responsible party
Sponsor
First posted
Apr 3, 2025
Start date
Aug 11, 2025
Primary completion
May 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Matthew Brobeck
Contact
matthew.brobeck@mabwell.com
801-201-4911
Eric Li
Contact
eric.li@mabwell.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bulumtatug fuvedotin

Start the discussion